Skip to content

PharmEasy is an Indian consumer healthcare platform offering online medicine ordering, diagnostic tests, and teleconsultations.

Last updated September 15, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

PharmEasy is described on its official site as a consumer healthcare "super app" providing on-demand, home-delivered access to prescription and OTC pharmaceutical products, other consumer healthcare products, diagnostic test services, and teleconsultations. Its offerings include medicine ordering, lab tests, doctor consultations, and branded substitutes, with delivery to 22,000+ pin codes and service to over 50 lakh families.

History

PharmEasy presents itself as India's leading digital Healthcare Platform and a consumer healthcare "super app". It offers on-demand, home-delivered access to prescription and OTC pharmaceutical products, other consumer healthcare products, diagnostic test services, and teleconsultations. As of June 30, 2021, it reported 25 million registered users; as of FY21, 8.8 million PharmEasy orders and 2.4 million transacting customers. Its platform lists 1 lakh+ medicines and health products through retail partners across the country, with delivery as low as 4 hours and guaranteed delivery in 24-48 hours.

Products and positioning

India's leading digital Healthcare Platform; a consumer healthcare "super app"

  • Order Medicine

    Order medicines & healthcare products online; 1 lakh+ medicines and health products across various categories through retail partners spread across the country.

  • Lab Tests

    Book diagnostic tests online.

  • Doctor Consult

    Teleconsultations as part of the consumer healthcare super app.

  • Branded Substitute

    Branded substitute offering with up to 50% off.

Recent events

  • Reported

    Vakrangee partners with PharmEasy to offer online healthcare services[5]

    Vakrangee Digital Ventures, a wholly owned subsidiary of Vakrangee Ltd, tied up with PharmEasy to provide online medicines and healthcare services to underserved populations in India through Vakrangee’s Nextgen Kendras and BharatEasy mobile app.

  • Unconfirmed

    Reported

    PharmEasy closes pre-IPO funding round[6]

    PharmEasy closed a pre-IPO funding round worth nearly $350 million. The article reports around $204 million in primary funding and says its parent, API Holdings, also closed a $130–$140 million secondary share sale; the round brought API Holdings’ post-money valuation to $5.6 billion, according to sources.

  • Unconfirmed

    Reported

    PharmEasy acquires Aknamed[7]

    PharmEasy acquired Aknamed in a stock-heavy deal valued at about $180–$190 million, with a small cash component, according to sources cited by the article.

  • Reported

    KBC 13 secures sponsors[8]

    Sony Entertainment Television announced that BYJU’S and Cadbury Dairy Milk would be co-presenting sponsors of KBC 13, with Hyundai Motor India, Asian Paints Royale Glitz, Ultratech Cement, Zydus Wellness (Complan), CERA, Pharmeasy, IDFC First Bank, LIC of India and Bharat Matrimony also joining as sponsors.

  • Reported

    BeatO raises Rs 42 crore in funding[9]

    BeatO said it raised Rs 42 crore in funding led by W Health Ventures, with participation from PharmEasy, Merisis VP and existing investors.

  • Reported

    PharmEasy completes acquisition of Medlife[10]

    PharmEasy said it completed its acquisition of Medlife, and that Medlife users would be migrated to PharmEasy.

Read more

Sources12 sources

Cite this profile: Cite the canonical profile. /brand-wiki/pharmeasy · Editorial policy · How profiles are compiled